ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Published Date: 22 Sep 2026

Early efficacy among the highest seen in lung cancer, expert says

Read Full News

Latest News

A Surgical First for Removal of an Appendiceal Neoplasm

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

— News, features, and commentary about cancer-related issues

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

FDA Advisors Recommend Galleri Multicancer Blood Test

Some panelists had reservations about the test's true benefit, however

FDA Approves New Option for Previously Treated Bile Duct Cancer

— Trial of lirafugratinib showed responses in almost half of patients, with good durability

Todays Updates

ASTRO: American Society for Radiation Oncology

Todays Updates

ASTRO: American Society for Radiation Oncology

Latest News

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

— News, features, and commentary about cancer-related issues

Case shows importance of accurate preop diagnosis

Some panelists had reservations about the test's true benefit, however

— Trial of lirafugratinib showed responses in almost half of patients, with good durability

News All Time

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Study Warns on Venetoclax in Double-Hit Lymphoma

Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

News, features, and commentary about cancer-related issues

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Death risk cut by 54% with B7-H3-targeting tambotatug pelitecan and risvutatug rezetecan

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Non-significant 4-month PFS increase with sacituzumab govitecan-pembrolizumab, no OS benefit

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Omitting prophylactic cranial irradiation led to improved cognitive failure-free survival

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Health news and commentary gathered by MedPage Today staff

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

All responding NCCN members reported shortages, priorities identified but solutions still needed

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

Bispecific antibody and ADC together impress in early study

Woman Develops Tiny Blood Spots on Her Body After COVID Shot

Case highlights need for quick diagnosis and management of rare disorder

Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

Ivonescimab topped pembrolizumab alone or paired with chemotherapy in separate trials

Patient's Colonoscopy Refusal Highlights Value of CRC Screening

Man with a first-degree relative with CRC initially only agreed to stool-based testing

Recommended News For You

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

Researchers discover that children who survive cancer have socioeconomic challenges.

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

FDA OKs Upfront Nivolumab+Chemo for Classic Hodgkin Lymphoma

Study finds primary-care doctors often overlook prostate cancer risk in Black men

AVD Chemo Regimen Shows Promise in Older Patients With HL

Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.

Recommended Articles For You

Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances 

A Closer Look at MCV Modules: Features, Functions, and Benefits  

Risk Assessment of Reduced Hematopoietic Reserve During Chronic Systemic Stress 

Acrochordon: What It Is, Causes, And How To Manage This Skin Condition 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How artificial intelligence could significantly improve the prognosis for cancer patients.

2.

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

3.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.

4.

How a California Oncologist Making $850k Spends Money

5.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

1.

What You Need to Know About the Early Warning Signs of Colon Cancer 

2.

Ferroptosis-Modulating Therapeutics in Precision Oncology

3.

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes

4.

Uncovering the Mysteries of the RDW Blood Test

5.

Ferroptosis Signaling in Tumor Progression and Therapeutic Resistance

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

2.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

3.

Understanding the Importance of Follow-Up After Cancer Treatment

4.

Efficient Management of First line ALK-rearranged NSCLC

5.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot